{"id":"W2053643895","doi":"10.1097/coc.0000000000000099","title":"Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)","year":2014,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Aegera Therapeutics (Canada)","funders":"Chinese University of Hong Kong; University of Hong Kong","keywords":"Sorafenib; Medicine; Hepatocellular carcinoma; Clinical endpoint; Internal medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Oncology; Combination therapy; Randomized controlled trial; Surgery; Phases of clinical research; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001833632,0.001686401,0.002871911,0.0003969464,0.0003391706,0.0007727605,0.0007310775,0.001072066,0.004518316],"category_scores_gemma":[0.001137335,0.0006763816,0.001148449,0.0003520353,0.001008933,0.0008329683,0.0004654566,0.002336612,0.0007902794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007079452,"about_ca_system_score_gemma":0.001412736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005125319,"about_ca_topic_score_gemma":0.001478454,"domain_scores_codex":[0.9994259,0.0003439304,0.00003348956,0.00009310644,0.00003868807,0.00006493669],"domain_scores_gemma":[0.999208,0.0001604306,0.0001959119,0.00005930644,0.0000429672,0.0003333594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9552023,0.01459188,0.001196168,0.0003793759,0.0008128337,0.000079212,0.00006747821,0.0007087329,0.01023277,0.00012782,0.000778153,0.01582337],"study_design_scores_gemma":[0.9271716,0.07030179,0.0009613161,0.000008083535,0.0001711741,0.0000421654,0.000009804136,0.0003105557,0.0006188087,0.00005724325,0.0003398833,0.000007606739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924456,0.001455253,0.0007567034,0.000471314,0.0002751327,0.003118056,0.0005634755,0.00008078364,0.0008336537],"genre_scores_gemma":[0.9891098,0.001211634,0.002197123,0.0006774703,0.0003154047,0.003691377,0.0008102877,0.00001879722,0.001968177],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004518316,"threshold_uncertainty_score":0.01511532,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01424811366629331,"score_gpt":0.3143347235867825,"score_spread":0.3000866099204892,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}